Michal Smahel

Laboratory Head

Charles University

Czech Republic

Research Interests

Explore related searches

Professors in Immunology

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Michal Smahel is a Laboratory Head at Charles University in the Czech Republic. His research areas include tumor immunology, specifically focusing on the role of aspartate β-hydroxylase in cancer and the immune response to tumors. Recent publications highlight his work on enhancing anti-tumor immunity, immunotherapy responses, and bioinformatics analysis related to cancer pathways.

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Collaborators (4)

Šárka Vaníková

Institute of Hematology and Transfusion Medicine

CZECH REPUBLIC

View details

Michal Holub

Head of the department

CZECH REPUBLIC

View details

Jana Šmahelová

Charles University

CZECH REPUBLIC

View details

Ondrej Vencalek

VSB - Technical University of Ostrava

CZECH REPUBLIC

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Michal Smahel

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Inhibition of Aspartate β-Hydroxylase Enhances Anti-Tumor Immunity

Spatial immune heterogeneity in a mouse tumor model after immunotherapy

Multiparametric analysis of the specific immune response against SARS-CoV-2

Aspartate-β-hydroxylase and hypoxia marker expression in head and neck carcinomas: implications for HPV-associated tumors

Aspartate β-hydroxylase Regulates Expression of <i>Ly6</i> Genes.

Heterogeneous Response of Tumor Cell Lines to Inhibition of Aspartate β-hydroxylase

Bioinformatics analysis of immune characteristics in tumors with alternative carcinogenesis pathways induced by human papillomaviruses.

Distinct Responsiveness of Tumor-Associated Macrophages to Immunotherapy of Tumors with Different Mechanisms of Major Histocompatibility Complex Class I Downregulation

ARG1 mRNA Level Is a Promising Prognostic Marker in Head and Neck Squamous Cell Carcinomas

CD80 Expression on Tumor Cells Alters Tumor Microenvironment and Efficacy of Cancer Immunotherapy by CTLA-4 Blockade

Collaborators (4)

Šárka Vaníková

Michal Holub

Jana Šmahelová

Ondrej Vencalek

Make your next move.